cisplatin 1mg/ml concentrate for solution for infusion
pfizer hellas ae (0000003442) 243 messoghion avenue, neo psychiko, athens, 15451 - cisplatin - concentrate for solution for infusion - 1mg/ml - cisplatin (0015663271) 1mg - cisplatin
doxorubicin-ebewe 2mg/ml solution for infusion, concentrate for
t.c.christoforou ltd - ΔΟΞΟΡΟΥΒΙΚΊΝΗ - solution for infusion, concentrate for - 2mg/ml - 0023214928 - doxorubicin - 2 mg - doxorubicin
alimax 80mg tablets
delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - telmisartan - tablets - 80mg - telmisartan (8000001673) 80mg - telmisartan
alimax 40mg tablets
delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - telmisartan - tablets - 40mg - telmisartan (8000001673) 40mg - telmisartan
eptifibatide accord
accord healthcare s.l.u. - επτιφιμπατίδη - Εμφραγμα μυοκαρδίου - Αντιθρομβωτικοί παράγοντες - Το eptifibatide accord προορίζεται για χρήση με ακετυλοσαλικυλικό οξύ και μη κλασματοποιημένη ηπαρίνη. Επτιφιμπατίδη accord ενδείκνυται για την πρόληψη του πρώιμου εμφράγματος του μυοκαρδίου σε ενήλικες που παρουσιάζουν ασταθή στηθάγχη ή χωρίς κύμα q έμφραγμα του μυοκαρδίου, με το τελευταίο επεισόδιο του πόνου στο στήθος που συμβαίνουν μέσα σε 24 ώρες και με ηλεκτροκαρδιογράφημα (ΗΚΓ) αλλαγές και/ή αυξημένα καρδιακά ένζυμα. Ασθενείς πιο πιθανό να επωφεληθούν από Επτιφιμπατίδη Συμφωνία μεταχείρισης αυτών που διατρέχουν υψηλό κίνδυνο εμφάνισης εμφράγματος του μυοκαρδίου μέσα στις πρώτες 3-4 ημέρες μετά την έναρξη της οξείας στηθάγχης συμπτώματα, όπως για παράδειγμα αυτές που είναι πιθανό να υποβληθούν σε πρώιμη αγγειοπλαστική (ptca) (Διαδερμική διαυλική Αγγειοπλαστική των Στεφανιαίων).
cytarabine 100mg/ml solution for injection
pharmaceutical trading co ltd (0000003066) 33 artemidos avenue, metropolitan court, larnaca, 6025 - cytarabine - solution for injection - 100mg/ml - cytarabine (0000147944) 100mg - cytarabine
asacol 400mg gastro resistant tablet
tillotts pharma gmbh (0000010051) warmbacher str. 80, rheinfelden, 79618 - mesalazine - gastro resistant tablet - 400mg - mesalazine (0000089576) 400mg - mesalazine
asacol 4g/100ml enema
tillotts pharma gmbh (0000010051) warmbacher str. 80, rheinfelden, 79618 - mesalazine - enema - 4g/100ml - mesalazine (0000089576) 4g - mesalazine
asacol 500mg suppositories
tillotts pharma gmbh (0000010051) warmbacher str. 80, rheinfelden, 79618 - mesalazine - suppositories - 500mg - mesalazine (0000089576) 0.500000000000g - mesalazine
jayempi
nova laboratories ireland limited - azathioprine - Απόρριψη μοσχεύματος - Ανοσοκατασταλτικά - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.